{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:34:04Z","timestamp":1790001244690,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2006,10]]},"DOI":"10.1016\/j.jns.2006.05.014","type":"journal-article","created":{"date-parts":[[2006,7,8]],"date-time":"2006-07-08T11:19:48Z","timestamp":1152357588000},"page":"78-83","source":"Crossref","is-referenced-by-count":36,"title":["Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms"],"prefix":"10.1016","volume":"248","author":[{"given":"L.","family":"Elmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schwid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Eberly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kieburtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Blindauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.L.","family":"Prisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Shoulson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2006.05.014_bib1","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/archneur.59.12.1937","article-title":"A controlled trial of rasagiline in early Parkinson's Disease (The TEMPO Study)","volume":"59","year":"2002","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2006.05.014_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo controlled trial of rasagiline in levodopa-treated Parkinson's disease patients with motor fluctuations (The PRESTO Study)","volume":"62","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2006.05.014_bib3","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archneur.56.7.785","article-title":"New and emerging therapies for Parkinson disease","volume":"56","author":"Jankovic","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2006.05.014_bib4","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2165\/00003495-200262050-00005","article-title":"Emerging therapies in the pharmacological treatment of Parkinson's disease","volume":"62","author":"Korczyn","year":"2002","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.jns.2006.05.014_bib5","first-page":"293","article-title":"Current concepts in the diagnosis and management of Parkinson's disease","volume":"168","author":"Guttman","year":"2003","journal-title":"CMAJ"},{"key":"10.1016\/j.jns.2006.05.014_bib6_1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1001\/archneur.60.12.1680","article-title":"Treatments of Parkinson disease: Circa 2003","volume":"60","author":"Shults","year":"2003","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2006.05.014_bib6_2","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/jama.284.15.1971","article-title":"Dopamine agonists in early therapy for Parkinson's disease: promise and problems","volume":"284","author":"Tanner","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2006.05.014_bib7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1001\/jama.284.15.1971","article-title":"Dopamine agonists in early therapy for Parkinson's disease: promise and problems","volume":"284","author":"Tanner","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jns.2006.05.014_bib8","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(77)90725-5","article-title":"Deprenyl in Parkinson's disease","volume":"2","author":"Lees","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.jns.2006.05.014_bib9","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/jnnp.43.11.1016","article-title":"Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa","volume":"43","author":"Schachter","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl. 126","key":"10.1016\/j.jns.2006.05.014_bib10","first-page":"113","article-title":"Selegiline in the treatment of daily fluctuations in disability of Parkinsonian patients with long-term levodopa treatment","volume":"80","author":"Heinonen","year":"1989","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jns.2006.05.014_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","article-title":"Deprenyl in the treatment of symptom fluctuation in advanced Parkinson's disease","volume":"11","author":"Golbe","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jns.2006.05.014_bib12","first-page":"163","article-title":"R-(\u2212)-deprenyl in the treatment of end-of-dose akinesia","volume":"25","author":"Ulm","year":"1987","journal-title":"J Neural Transm Suppl"},{"key":"10.1016\/j.jns.2006.05.014_bib13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00002826-199302000-00010","article-title":"Effect of selegiline dosing on motor fluctuations in Parkinson's disease","volume":"16","author":"Hubble","year":"1993","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.jns.2006.05.014_bib14","article-title":"Ropinirole for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.jns.2006.05.014_bib15","article-title":"Pramipexole for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"10.1016\/j.jns.2006.05.014_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200241040-00003","article-title":"Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease","volume":"41","author":"Deleu","year":"2002","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.jns.2006.05.014_bib17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/00002018-200326060-00005","article-title":"Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis","volume":"26","author":"Etminan","year":"2003","journal-title":"Drug Safety"},{"issue":"11","key":"10.1016\/j.jns.2006.05.014_bib18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2165\/00002018-200124110-00007","article-title":"Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials","volume":"24","author":"Etminan","year":"2001","journal-title":"Drug Safety"},{"issue":"1","key":"10.1016\/j.jns.2006.05.014_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2165\/00003495-199958010-00017","article-title":"Entacapone. A review of its use in Parkinson's disease","volume":"58","author":"Holm","year":"1999","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jns.2006.05.014_bib20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/00002826-200009000-00004","article-title":"A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease","volume":"23","author":"Inzelberg","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.jns.2006.05.014_bib21","first-page":"101","article-title":"A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease","volume":"21","author":"Brooks","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.jns.2006.05.014_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1212\/WNL.49.2.393","article-title":"Ropinirole for the treatment of early Parkinson's disease","volume":"49","author":"Adler","year":"1997","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jns.2006.05.014_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1001\/jama.278.2.125","article-title":"Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study","volume":"278","year":"1997","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jns.2006.05.014_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00002826-199508000-00006","article-title":"Pramipexole in patients with early Parkinson's disease","volume":"18","author":"Hubble","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.jns.2006.05.014_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","article-title":"Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease","volume":"19","author":"Rascol","year":"1996","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.jns.2006.05.014_bib26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2006.05.014_bib27","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2006.05.014_bib28","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jns.2006.05.014_bib29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1468-1331.1998.530235.x","article-title":"A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease","volume":"5","author":"Wermuth","year":"1998","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2006.05.014_bib30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2006.05.014_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month Study","volume":"74","author":"Brooks","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.jns.2006.05.014_bib32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in Parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2006.05.014_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jns.2006.05.014_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","article-title":"Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study","volume":"110","author":"Fenelon","year":"2003","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2006.05.014_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0404.1997.tb00101.x","article-title":"Selegiline as the primary treatment of Parkinson's disease \u2014 a long-term double-blind study","volume":"95","author":"Myllyla","year":"1997","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 1","key":"10.1016\/j.jns.2006.05.014_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000116869","article-title":"An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease","volume":"32","author":"Shoulson","year":"1992","journal-title":"Eur Neurol"},{"issue":"5","key":"10.1016\/j.jns.2006.05.014_bib37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00002826-200009000-00006","article-title":"Adverse drug reactions to selegiline: a review of the French pharmacovigilance database","volume":"23","author":"Montastruc","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"1","key":"10.1016\/j.jns.2006.05.014_bib38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002512-200016010-00005","article-title":"Comparative tolerability of the newer generation antiparkinsonian agents","volume":"16","author":"Lambert","year":"2000","journal-title":"Drugs Aging"},{"issue":"4","key":"10.1016\/j.jns.2006.05.014_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.parkreldis.2004.01.006","article-title":"Therapeutic factors causing hallucination in Parkinson's disease patients, especially those given selegiline","volume":"10","author":"Kamakura","year":"2004","journal-title":"Parkinsonism Relat Disord"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X06002061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X06002061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T22:54:58Z","timestamp":1555714498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X06002061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":40,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["S0022510X06002061"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2006.05.014","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}